Extended Data Table 3 IVORY-FINALE study secondary outcomes

From: Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial

  1. No. (%), number of participants (percentage of participants).
  2. All events that occurred have been declared at 2 years of follow-up. One patient had three secondary outcome events after the index event (myocardial infarction, an unplanned coronary revascularization and death due to a cardiovascular cause).
Back to article page